Potential relationship between Hashimoto's thyroiditis and BRAF<sup>V600E</sup> mutation status in papillary thyroid cancer

Zeng, Rui-chao; Jin, Liu; Chen, Endong; Dong, Siyang; Cai, Yefeng; Huang, Guiqian; Li, Quan; Jin, Chen; Zhang, Xiaohua; Wang, Ouchen

doi:10.1002/hed.24149

Cited by 39 publications

(27 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies have shown that HT is negatively associated with BRAF V600E mutation, extrathyroidal extension and lymph node metastasis. Moreover, even if there is a BRAF V600E mutation, HT can also inhibit the proliferation of thyroid and lymph node metastasis [9,10]. Our data support that HT is a protective factor of PTC.…”

Section: Discussionsupporting

confidence: 75%

“…Some studies have shown that HT may be a protective factor in PTC, and is negatively correlated with BRAF V600E mutation, extra thyroid proliferation and lymph node metastasis. Moreover, even if BRAF V600E is mutated, PTC patients accompanied with HT have less extrathyroidal extension and lymph node metastasis [9,10]. BRAF V600E mutation is the most common genetic variants of PTC.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Hashimoto’s thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients

et al. 2018

neo

View full text Add to dashboard Cite

Papillary thyroid carcinoma (PTC) is often combined with other types of thyroid disease, such as Hashimoto's thyroiditis(HT), nodular goiter(NG), Follicular adenoma(FA) and other types. However, the function of these diseases in PTC tumorigenesis and development is not well understood. In this research, 563 PTC patients were recruited and divided into two groups according to pathological diagnosis, namely simple PTC (PTC) and PTC combined with other thyroid diseases (PTC+). Clinicopathological characteristics and BRAFV600E mutation status were compared between PTC and PTC+. Our data showed that there was a statistically significant difference in gender (P=0.007), tumor diameter (5mm, P=0.012; 1cm, P=0.042), lymph node metastasis (P=0.000) and BRAFV600E mutation status (P=0.001) between PTC and PTC+. PTC+ patients have lower lymph node metastasis rate, even if PTC nodule diameter is larger than 5mm (P=0.005) or ≥1cm (P=0.049) or BRAFV600E is mutated (P=0.001). In conclusion, our study suggests that HT, NG and FA, are protective factors of PTC patients, and PTC+ patients have lower lymph node metastasis and BRAFV600E mutation rate compared with simple PTC patients.

show abstract

Section: Discussionsupporting

confidence: 75%

mentioning

confidence: 99%

Hashimoto’s thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients

et al. 2018

neo

View full text Add to dashboard Cite

show abstract

“…Relationship between Hashimoto's disease and RET-PTC chromosome translocation in PTC has long been discussed [6,62]. PTC with BRAF V600E , another important driver mutation in PTC, has been well known to be more aggressive than PTC without the mutation [63,64].…”

Section: Is Thyroid Autoimmunity Beneficial For or Harmful Against Thmentioning

confidence: 99%

“…PTC with BRAF V600E , another important driver mutation in PTC, has been well known to be more aggressive than PTC without the mutation [63,64]. In contrast to RET-PTC which is frequently associated with Hashimoto's thyroiditis, several studies show that the presence of BRAF V600E is negatively associated with lymphocyte infiltration, and is protective for aggressiveness of PTC [62,[65][66][67].…”

Section: Is Thyroid Autoimmunity Beneficial For or Harmful Against Thmentioning

confidence: 99%

Thyroid Autoimmunity and Thyroid Cancer – The Pathogenic Connection: A 2018 Update

Nagayama

2018

Horm Metab Res

View full text Add to dashboard Cite

The association between thyroid cancer and thyroid autoimmunity has long been suggested, but remains to be elucidated for several decades. Here the data on this issue are updated by summarizing relevant papers published between 2012 and early 2018. Although numerous papers demonstrated the significant increase in the prevalence of thyroid autoimmunity (positive intrathyroidal lymphocyte infiltration and/or anti-thyroglobulin/thyroid peroxidase antibodies) in patients with thyroid cancers as compared to those with benign nodules, and also the significant increase in the prevalence of papillary thyroid cancer (PTC) in patients with thyroid autoimmunity as compared to those without, there are some crucial biases that should be taken into account for their interpretation. However, a difference in the incidence of thyroid autoimmunity in patients with PTCs and those with other types of thyroid cancers appears to support the significant association of two conditions. Thyroid autoimmunity is, at least partly, likely to be elicited against antigens shared by normal and cancerous thyroid tissues, thereby inducing autoimmunity. At the same time, elevated TSH levels (even within the normal reference ranges), which often accompany Hashimoto's patients are a risk factor for thyroid cancer. However, it is still unclear whether or not the co-existence of thyroid autoimmunity impacts on cancer characteristics and prognosis. This issue needs to be further investigated with large-scale prospective studies.

show abstract

“…Hashimoto's thyroiditis was negatively associated with BRAF V600E mutation, extrathyroidal extension in papillary carcinoma with BRAF V600E mutation. The conclusion is that Hashimoto's thyroiditis and lymphocytic infiltration of Hashimoto's thyroiditis are a potentially protective factor in papillary carcinoma against its progression, and it is independent of BRAF mutational status [43][44][45]. In a study, no BRAF or RAS mutations or RET-PTC rearrangements were identified in the dominant nodule in Hashimoto's thyroiditis [46].…”

mentioning

confidence: 93%

Hashimoto’s Thyroiditis and Thyroid Cancer

Sanchis¹

2016

View full text Add to dashboard Cite

show abstract

Potential relationship between Hashimoto's thyroiditis and BRAF^V600E mutation status in papillary thyroid cancer

Cited by 39 publications

References 50 publications

Hashimoto’s thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients

Hashimoto’s thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients

Thyroid Autoimmunity and Thyroid Cancer – The Pathogenic Connection: A 2018 Update

Hashimoto’s Thyroiditis and Thyroid Cancer

Contact Info

Product

Resources

About

Potential relationship between Hashimoto's thyroiditis and BRAFV600E mutation status in papillary thyroid cancer

Cited by 39 publications

References 50 publications

Hashimoto’s thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients

Hashimoto’s thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients

Thyroid Autoimmunity and Thyroid Cancer – The Pathogenic Connection: A 2018 Update

Hashimoto’s Thyroiditis and Thyroid Cancer

Contact Info

Product

Resources

About

Potential relationship between Hashimoto's thyroiditis and BRAF^V600E mutation status in papillary thyroid cancer